YD Bio (YDES) Total Liabilities (2024 - 2025)
YD Bio's (YDES) quarterly Total Liabilities came in at $16.6 million in Q4 2025, up 5971.63% year-on-year from $273980.0 in Q4 2024, and up 2109.36% on a QoQ basis from $752935.0 in Q2 2025.
YD Bio (YDES) Total Liabilities (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Total Liabilities data on file, last reported at $16.6 million in Q4 2025.
- On a quarterly basis, Total Liabilities rose 5971.63% year-over-year to $16.6 million in Q4 2025; TTM through Dec 2025 was $16.6 million, a 5971.63% increase from a year earlier, with the FY2025 full-year figure at $16.6 million, up 5971.63% from the prior year.
- Total Liabilities for Q4 2025 stood at $16.6 million, up from $752935.0 in the prior quarter.
- Over the last five years, Total Liabilities for YDES reached as high as $16.6 million in Q4 2025 and fell as low as $273980.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 177.22 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.51 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 3.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.62 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 753.82 Mn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 16.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.64 Mn |
| Jun 30, 2025 | 752,935.00 |
| Dec 31, 2024 | 273,980.00 |